[Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic]. / Metaanálisis para evaluar el riesgo de infecciones respiratorias y síndrome de distrés respiratorio del adulto con los agonistas del receptor del péptido similar al glucagón tipo 1 en los ensayos de seguridad cardiovascular: consecuencias útiles para la pandemia de COVID-19.
Rev Clin Esp
; 222(4): 229-232, 2022 Apr.
Article
in Spanish
| MEDLINE | ID: covidwho-1211127
ABSTRACT
Patients with type 2 diabetes mellitus (T2DM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and related mortality. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have significant cardiovascular and renal benefits for patients with T2DM and related comorbidities. Their anti-inflammatory properties could be beneficial in these patients. This work provides less-biased estimates regarding the risk for respiratory tract infections and acute respiratory distress syndrome by performing the first significant meta-analysis of cardiovascular outcome trials in the literature. Notably, GLP-1-RAs do not seem to increase the risk for respiratory tract infection, pneumonia, or acute respiratory distress syndrome in patients with T2DM and cardiovascular comorbidities.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Experimental Studies
/
Prognostic study
/
Reviews
Language:
Spanish
Journal:
Rev Clin Esp
Journal subject:
Medicine
Year:
2022
Document Type:
Article
Affiliation country:
J.rce.2021.04.001
Similar
MEDLINE
...
LILACS
LIS